Congratulations to our Neuroendocrine Tumour (NET) service, who have been re-accredited as a Centre of Excellence following an inspection earlier this year by the European NET Society (ENETS).
The Liverpool NET service has now held this status for 15 years, which is a huge achievement and demonstrates our continued excellence in the field of NET, where patients are often highly complex, and need a multidisciplinary approach to care.
NET is a rare type of tumour that can develop in several places in the body, but most commonly in the gastrointestinal (GI) tract and pancreas. Their severity can vary, with most being slow growing and patients can live relatively normally if the tumour is kept stable through regular medicine and treatment. However around 10-20% of tumours (neuroendocrine carcinomas) can be more aggressive and require more urgent care.
One of only 60 centres across Europe, the Liverpool NET service was established over 25 years ago and is the second busiest in the UK. Annually, the team see 250-300 new referrals into the service and will often care for patients over a time frame of 10 to 20 years – meaning thousands of patients are receiving life-saving specialist treatment as a result of this fantastic team.
Mark Pritchard, Honorary Consultant Gastroenterologist and NET MDT clinical lead at University Hospitals of Liverpool Group, said: “I’m incredibly proud of the team and the recognition the service has received in being reaccredited once again as a Centre of Excellence by ENETS”.
“It’s an incredible multidisciplinary effort to provide the comprehensive service that NET patients need, and I’d like to thank every colleague who is involved in this pathway and supports us to deliver high quality care.”